← Back to Search

GLP-1/Glucagon Receptor Agonist

MEDI0382 low dose + Metformin for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time points at which outcome measure were assessed for plasma concentration were weeks 1,2,6,10,14,18,22,26, and 54
Awards & highlights

Summary

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time points at which outcome measure were assessed for plasma concentration were weeks 1,2,6,10,14,18,22,26, and 54
This trial's timeline: 3 weeks for screening, Varies for treatment, and time points at which outcome measure were assessed for plasma concentration were weeks 1,2,6,10,14,18,22,26, and 54 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Absolute Change in Body Weight
Absolute Change in Body Weight Versus Active Comparator
Change in HbA1c
+8 more

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: MEDI0382 mid dose + MetforminExperimental Treatment1 Intervention
Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
Group II: MEDI0382 low dose + MetforminExperimental Treatment1 Intervention
Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
Group III: MEDI0382 high dose + MetforminExperimental Treatment1 Intervention
Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
Group IV: Liraglutide + MetforminActive Control1 Intervention
Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
Group V: Placebo + MetforminPlacebo Group1 Intervention
Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Metformin
FDA approved
Metformin
FDA approved
Cotadutide
Not yet FDA approved

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,302 Previous Clinical Trials
288,623,765 Total Patients Enrolled
MedImmune LLCIndustry Sponsor
347 Previous Clinical Trials
793,075 Total Patients Enrolled
~105 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top